Pular para o conteúdo
Menu
Mix Vale

Anvisa halts sale of Glicopill diabetes supplement due to licensing breaches and unproven claims

Luís Pereira
Por 6 min de leitura
Compartilhe
anvisa
Foto: anvisa - Poetra.RH/Shutterstock.com

Brazilian health authorities recently announced a nationwide ban on specific products from two companies, Ervas Brasil and Glicopill. The Agência Nacional de Vigilância Sanitária (Anvisa) determined that both firms lacked the essential Sanitary License and Operating Permit required to manufacture and distribute health products. This measure, effective in early 2025, impacts several items, including a highly marketed diabetes supplement.

Publicidade

Among the products immediately targeted for apprehension and sales prohibition is Glicopill’s oral supplement, which aggressively promoted its ability to control blood glucose using natural ingredients. Anvisa has mandated the removal of this product from all online sales and advertising platforms, preventing any further commercialization.

Publicidade

This regulatory action underscores Anvisa’s commitment to protecting public health by ensuring that all health products available to consumers meet strict safety and efficacy standards. The absence of fundamental licensing indicates a serious breach of regulatory protocols, posing potential risks to users.

Regulatory action targets unlicensed operations

The primary catalyst for Anvisa’s decisive action against Ervas Brasil and Glicopill in 2025 was the pervasive lack of proper regulatory authorization. Companies operating within the health sector in Brazil are strictly required to possess a Sanitary License, which certifies adherence to health and safety standards, and an Operating Permit, allowing legal business operations. The absence of these foundational documents rendered all their products non-compliant and illegal for sale.

This recent directive extends beyond online platforms, encompassing all physical retail locations and distribution channels where the affected products might be found. Inspectors across Brazil are being briefed to ensure swift compliance, seizing products and preventing any further dissemination, protecting consumers from potentially unsafe or ineffective items.

Unsubstantiated claims raise health concerns

The Glicopill supplement, specifically designed to address diabetes, utilized extensive social media promotion to make a series of bold health claims. Its marketing suggested it could “directly attack the root of type 2 diabetes, decrease dependence on medications, transform health from the inside out, control glucose without harming the body, restore energy and disposition, and aid circulation and heart health.” Such comprehensive health promises for a dietary supplement are typically met with extreme scrutiny and require rigorous scientific validation, which Glicopill notably failed to provide.

These types of unsubstantiated claims are particularly dangerous when targeting serious medical conditions like diabetes, which requires precise medical management. Consumers relying on unproven supplements in place of prescribed treatments risk severe health complications, including uncontrolled blood sugar levels, kidney damage, vision loss, and other long-term consequences. Anvisa’s swift intervention aims to mitigate these public health risks by removing products that offer false hope and potentially harmful alternatives.

Publicidade

History of non-compliance for manufacturers

This is not the first instance of Anvisa taking action against the companies involved. Products from Ervas Brasil, including “Vitamin C Sucupira with Cat’s Claw” and a “cholesterol supplement,” had already been prohibited from sale by the regulatory body. These earlier bans stemmed from the same critical issues: the absence of a Sanitary License and an Operating Permit, highlighting a persistent pattern of regulatory non-compliance.

The repeated infractions demonstrate a systemic failure by these companies to meet basic legal and health requirements for product manufacturing and distribution. Such a history reinforces Anvisa’s stance that stricter measures, including full apprehension and prohibition, are necessary to safeguard the public from businesses operating outside established legal frameworks.

Consumer vigilance essential for supplement purchases

Consumers are urged to exercise extreme caution when purchasing health supplements, particularly those making dramatic claims about curing or managing chronic diseases. It is crucial to verify the legitimacy of both the product and the manufacturer. Before purchasing any supplement, individuals should check if the product is registered or approved by Anvisa and if the company possesses the necessary licenses.

Reliance on advice from healthcare professionals, such as doctors or dietitians, remains paramount, especially for conditions requiring medical supervision. Supplements should complement, not replace, prescribed medical treatments and lifestyle modifications. Anvisa’s official website provides a comprehensive database where consumers can check product registrations and company licenses, serving as a vital resource for informed health decisions.

Risks associated with unregulated health products

The proliferation of unregulated health products poses significant and varied risks to public health. Without proper licensing and oversight, there is no guarantee regarding the safety, purity, or actual content of these supplements. Products might contain undeclared ingredients, contaminants, or incorrect dosages, leading to adverse health reactions, interactions with medications, or simply being ineffective.

Furthermore, products making unverified therapeutic claims can mislead consumers into delaying or abandoning evidence-based medical treatments. This can be particularly detrimental for individuals with chronic conditions like diabetes, where consistent and medically supervised care is essential for disease management and prevention of severe complications. Anvisa’s robust regulatory framework exists precisely to prevent such public health hazards.

Anvisa’s ongoing commitment to public health

Anvisa continually monitors the market for non-compliant products and fraudulent health claims, employing a multi-faceted approach to consumer protection. This includes proactive inspections, responding to consumer complaints, and collaborating with other enforcement agencies to identify and remove illegal products from circulation. The agency’s actions are guided by scientific evidence and public health priorities, ensuring that only safe and effective products reach the Brazilian market.

The ban on Glicopill and Ervas Brasil products is a clear demonstration of Anvisa’s unwavering commitment to its mandate. It serves as a reminder to manufacturers that adherence to regulatory standards is non-negotiable and to consumers that vigilance is key in making health-related purchasing decisions. The authority remains dedicated to upholding the integrity of the health product market.

What consumers should know about product legality

For consumers seeking to ensure the legality and safety of health products in Brazil, several key indicators can help distinguish legitimate items from prohibited ones. Anvisa stresses the importance of checking official sources for product information and manufacturer credentials.

* Always verify if a product has an Anvisa registration number or notification. This information is typically found on the product packaging.
* Check the manufacturer’s licensing status directly on Anvisa’s official portal. Legitimate companies will have valid sanitary licenses and operating permits.
* Be wary of products that promise “miraculous” cures or make overly aggressive health claims without scientific backing. These are often red flags for unregulated items.
* Consult with a healthcare professional before incorporating any new supplement into your regimen, especially if you have existing health conditions or are taking other medications.

These steps can significantly reduce the risk of purchasing and consuming potentially harmful or ineffective products, aligning with Anvisa’s ongoing efforts to promote public health and safety.

Publicidade

Luís Henrique Costa é jornalista formado pela FMU, editor-chefe e fundador do Mix Vale, portal de notícias em atividade desde 2011. Responde pela direção editorial do veículo, que cobre Brasil e mundo em economia, benefícios sociais, esportes, tecnologia, ciência e entretenimento. Atua na área há mais de 15 anos e lidera uma equipe de cerca de 15 colaboradores.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto